Toronto, Ontario--(Newsfile Corp. - February 11, 2022) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) ("VIVO" or the "Company"), a leading provider of medical cannabis products and patient services, and holder of licenses under the Cannabis Act through its wholly-owned subsidiaries, Canna Farms Limited ("Canna Farms") and ABcann Medicinals Inc., today announced a partnership with Cicatrix Labs Ltd. ("Cicatrix Labs") to offer Assuage™ vaginal and rectal suppositories on VIVO's Canna Farms e-commerce marketplace.
"In keeping with our laser focused medical strategy, we are extremely proud to be the first legal medical marketplace in Canada to launch the broadest range of suppositories available to all Canadian patients," commented Ray Laflamme, Canna Farms' Co-Founder and VIVO's Chief Executive Officer. "We've listened to our patients and advocacy groups, and we have recognized an unmet need for this specialized dosage format to support various women's health conditions gastrointestinal health conditions affecting both men and women."
Assuage™ suppositories for vaginal and rectal use are available in two formulations: 50 mg cannabidiol (CBD), and 1:3 formulation of 10 mg tetrahydrocannabinol (THC) and 30 mg CBD, with 8 suppositories per tin package.
"Assuage means to 'ease, or make an unpleasant feeling less intense', and these suppositories were designed keeping patient comfort and efficacy in mind for those unable to obtain relief with oral or inhaled cannabis," commented Sarah Roberts, RPh, President and Founder of Cicatrix Labs. "Patients no longer have to purchase suppositories from the illegal market or make their own. Partnering with Canna Farms ensures broad access of this unique dosage format for tens of thousands of patients."
VIVO Cannabis™ Adds Assuage Suppositories to Online Medical Marketplace
To view an enhanced version of this graphic, please visit:
VIVO is committed to its patient-first approach ensuring access to novel cannabinoid-based formulations. These newly launched Assuage vaginal and rectal suppositories are exclusively available through the Canna Farms e-commerce medical marketplace for Canadian medical clients. Patients requiring support with registration or placing orders can contact VIVO's Customer Care Team at 1 (855) 882-0988 or email@example.com.
About VIVO Cannabis™
VIVO Cannabis™ is recognized for trusted, premium cannabis products and services. It holds production and sales licences from Health Canada and operates world-class cultivation facilities. VIVO has a collection of medical, health and wellness brands, each targeting different customer segments, including Canna Farms™, Beacon Medical™, Fireside™, and Lumina™. Harvest Medicine™, VIVO's patient-centric, scalable network of medical cannabis clinics, has serviced over 200,000 patient visits. VIVO is pursuing several partnership and product development opportunities and is focusing its international efforts on Germany and Australia. For more information visit: www.vivocannabis.com.
About Cicatrix Labs
Cicatrix Labs is a pharmacist-founded manufacturer of unique cannabinoid-infused products including topicals and suppositories. Cicatrix Labs offers an in-house line of personal care products to Licensed Producers and Medical License holders as well as custom white labeled products.
For further information:
VIVO Investor Relations
Disclaimer for Forward-Looking Information
Certain statements in this news release are forward-looking statements, which are statements that are not purely historical, including statements regarding the beliefs, plans, expectations or intentions of VIVO and its management regarding the future. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward‐looking statements. No assurance can be given that any of the events anticipated by the forward‐looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully along with the more extensive risk factors included in the Company's most recent management's discussion and analysis available on SEDAR, in evaluating the forward‐looking statements contained in this news release and are cautioned not to place undue reliance on such forward‐looking statements, which are qualified in their entirety by these cautionary statements. The forward‐looking statements in this news release are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any such forward‐looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/113526